← Addex Therapeutics Ltd.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income | — | — | — | — | — | ($20.8m) |
($10.6m)
+49.26%
|
$7.1m
+166.84%
|
($6.7m)
-195.36%
|
($7.0m)
-3.55%
|
|
| Share of the net loss of associates | — | — | — | — | — | — | — | $2.2m | $4.0m | — | |
| Profit or Loss | — | ($1.6m) | ($14.8m) | ($12.9m) | ($15.4m) | ($20.8m) | ($10.6m) | $7.1m | — | — | |
| Depreciation | $15k | $3k | $334k | $379k | $348k | $323k | $306k | $260k | $8k | $16k | |
| Adjustments For Share-Based Payments | — | $2.3m | $1.7m | $1.2m | $1.2m | $3.7m | $1.8m | $503k | — | — | |
| Value of share-based services | $800k | $2.3m | $1.7m | $1.2m | $1.2m | $3.7m | $1.8m | $503k | $71k | — | |
| Earnings (Loss)es From Equity Investments | — | — | — | — | — | $0 | $0 | $2.2m | $4.0m | $4.4m | |
| Change In Working Capital | — | — | — | — | — | $158k | $214k | ($1.2m) | $549k | $251k | |
| Decrease / (increase) in trade and other receivables | ($83k) | ($77k) | $155k | $50k | ($96k) | ($252k) | $307k | $93k | ($5k) | — | |
| Change In Receivables | — | — | — | — | — | ($274k) | $447k | $134k | ($5k) | $3k | |
| Changes In Account Receivables | — | — | — | — | — | ($252k) | $307k | $93k | ($5k) | $3k | |
| Increase / (decrease) in payables and accruals | ($212k) | $1.1m | $2.0m | ($1.6m) | $884k | ($427k) | ($613k) | ($1.1m) | $391k | — | |
| Change In Payables And Accrued Expense | — | — | — | — | — | ($427k) | ($613k) | ($1.1m) | $391k | $135k | |
| Decrease / (increase) in other current assets | — | — | — | — | — | — | — | ($8k) | $8k | — | |
| Change In Other Current Assets | — | — | — | — | — | $14k | $2k | ($14k) | $9k | $4k | |
| Purchase of property, plant and equipment | ($697) | ($9k) | ($28k) | ($59k) | ($32k) | ($581) | ($7k) | ($1k) | $0 | — | |
| Net cash from/(used in) investing activities | ($697) | ($56k) | ($43k) | ($59k) | ($30k) | $3k | ($7k) | $4.6m | ($681k) | — | |
| Net Issuance Payments Of Debt | — | — | — | — | — | ($288k) | ($282k) | ($74k) | ($7k) | ($7k) | |
| Net Long Term Debt Issuance | — | — | — | — | — | ($288k) | ($282k) | ($74k) | ($7k) | ($7k) | |
| Long Term Debt Payments | — | — | — | — | — | ($288k) | ($282k) | ($74k) | ($7k) | ($7k) | |
| Repayment Of Debt | — | — | — | — | — | ($288k) | ($282k) | ($74k) | ($7k) | ($7k) | |
| Issuance Of Capital Stock | — | — | — | — | — | $1.7m | $2.4m | $241k | $1.2m | $1.2m | |
| Repurchase Of Capital Stock | — | — | — | — | — | ($3k) | ($48k) | ($26k) | ($29k) | ($32k) | |
| Common Stock Issuance | — | — | — | — | — | $1.7m | $2.4m | $241k | $1.2m | $1.2m | |
| Net Common Stock Issuance | — | — | — | — | — | $1.7m | $2.3m | $215k | $1.2m | $1.2m | |
| Common Stock Payments | — | — | — | — | — | ($3k) | ($48k) | ($26k) | ($29k) | ($32k) | |
| Cash Dividends Paid | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Net Other Financing Charges | — | — | — | — | — | ($523k) | $10k | $9k | ($6k) | ($9k) | |
| Net cash from financing activities | $3.4m |
$37.4m
+1014.31%
|
($464k)
-101.24%
|
$46k
+110.01%
|
$16.4m
+35251.68%
|
$3.1m
-81.08%
|
$5.3m
+69.68%
|
$105k
-98.01%
|
$1.2m
+1028.37%
|
— | |
| Beginning Cash Position | — | — | — | — | — | $20.5m | $7.0m | $3.9m | $3.3m | $2.8m | |
| Cash and cash equivalents at beginning of the year | $2.6m | $41.7m | $31.5m | $18.7m | $20.5m | $7.0m | $3.9m | $3.3m | $1.6m | — | |
| Effect Of Exchange Rate Changes | — | — | — | — | — | ($196k) | ($357k) | $100k | ($35k) | ($23k) | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Additional Financial Items | |||||||||||
| Adjustments For Finance Costs | — | $124k | $235k | $687k | — | — | — | — | — | — | |
| Adjustments For Undistributed Profits Of Associates | — | — | — | — | — | — | — | ($2.2m) | — | — | |
| General And Administrative Expense | — | $3.2m | $5.0m | $5.7m | $5.8m | $7.3m | $5.0m | $2.3m | — | — | |
| Payments Of Lease Liabilities Classified As Financing Activities | — | — | $317k | $367k | $310k | $288k | $282k | $74k | — | — | |
| Proceeds From Issuing Shares | — | $40.5m | — | — | $10.2m | — | — | — | — | — | |
| Net profit / (loss) for the period | ($3.3m) | ($1.6m) | ($14.8m) | ($12.9m) | ($15.4m) | ($20.8m) | ($10.6m) | $7.1m | ($6.7m) | — | |
| Net gain on Neurosterix Transaction | — | — | — | — | — | — | — | ($13.9m) | ($114k) | — | |
| Post-employment benefits | $20k | $20k | $97k | ($23k) | ($150k) | ($11k) | ($63k) | ($95k) | ($7k) | — | |
| Net gain related to lease modification | — | — | — | — | — | — | ($318) | ($3k) | — | — | |
| Finance cost / (income) net | — | — | $235k | $687k | ($132k) | $216k | $313k | ($100k) | $38k | — | |
| Decrease / (increase) in other financial assets | ($5k) | $3k | ($6k) | ($51k) | $48k | $14k | $2k | ($6k) | $1k | — | |
| Decrease in contract asset | — | — | — | — | ($160k) | ($22k) | $141k | $41k | — | — | |
| Decrease / (increase) in prepayments | — | — | ($521k) | $222k | ($617k) | $845k | $53k | ($164k) | $153k | — | |
| Decrease in deferred income | — | — | $331k | ($244k) | ($86k) | — | $324k | ($38k) | — | — | |
| Consideration from Neurosterix Transaction | — | — | — | — | — | — | — | $5.1m | $114k | — | |
| Sale of treasury shares | — | — | — | — | — | — | $2.4m | $241k | $1.2m | — | |
| Cost paid on sale of treasury shares | — | — | — | — | — | — | ($48k) | ($26k) | ($29k) | — | |
| Cost of treasury share issuance | — | — | — | — | — | ($248k) | ($54k) | — | ($6k) | — | |
| Proceeds from the exercise of pre-funded warrants | — | — | — | — | — | $25k | $36k | — | — | — | |
| Costs paid on exercise of pre-funded warrants | — | — | — | — | — | ($576k) | ($21k) | ($36k) | — | — | |
| Principal element of lease payment | — | — | ($317k) | ($367k) | ($310k) | ($288k) | ($282k) | ($74k) | ($7k) | — | |
| Interest received | — | — | $37k | $35k | $5k | $29k | $64k | $9k | — | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | $3.1m | $5.3m | $105k | $1.2m | $1.2m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | $3k | ($7k) | $4.6m | ($681k) | ($681k) | |
| Change In Other Working Capital | — | — | — | — | ($820k) | — | $324k | ($38k) | — | ($38k) | |
| Change In Prepaid Assets | — | — | — | — | — | $845k | $53k | ($164k) | $153k | $109k | |
| Changes In Cash | — | — | — | — | — | ($13.3m) | ($2.7m) | ($623k) | ($1.7m) | ($1.9m) | |
| End Cash Position | — | — | — | — | — | $7.0m | $3.9m | $3.3m | $1.6m | $958k | |
| Financing Cash Flow | — | — | — | — | — | $3.1m |
$5.3m
+69.68%
|
$105k
-98.01%
|
$1.2m
+1028.37%
|
$1.2m
-2.75%
|
|
| Free Cash Flow | — | — | — | — | — | ($16.4m) | ($8.0m) | ($5.4m) | ($2.2m) | ($2.3m) | |
| Gain Loss On Sale Of Business | — | — | — | — | — | $0 | $0 | ($13.9m) | ($114k) | ($114k) | |
| Gain Loss On Sale Of PPE | — | — | — | — | ($127) | $0 | — | — | — | — | |
| Investing Cash Flow | — | — | — | — | — | $3k | ($7k) | $4.6m | ($681k) | ($681k) | |
| Net Business Purchase And Sale | — | — | — | — | — | $0 | $0 | $5.1m | $114k | $114k | |
| Net PPE Purchase And Sale | — | — | — | — | — | ($581) | ($7k) | ($1k) | $0 | $0 | |
| Operating Gains Losses | — | — | — | — | — | ($11k) | ($63k) | ($11.9m) | $3.9m | $4.3m | |
| Other Non Cash Items | — | — | — | — | — | $3.9m | $2.1m | $401k | $108k | — | |
| Pension And Employee Benefit Expense | — | — | — | — | — | ($11k) | ($63k) | ($95k) | ($7k) | ($13k) | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | $2.3m | $3.3m | ($36k) | $0 | $0 | |
| Purchase Of Business | — | — | — | — | — | $0 | $0 | ($473k) | — | ($20k) | |
| Purchase Of PPE | — | — | — | — | — | ($581) | ($7k) | ($1k) | $0 | ($1k) | |
| Sale Of Business | — | — | — | — | — | — | $0 | $5.1m | $114k | $114k | |
| Stock Based Compensation | — | — | — | — | $1.2m | $3.7m | — | — | — | — | |
| Net Investment Purchase And Sale | — | — | — | — | — | $4k | $0 | $0 | ($795k) | ($795k) | |
| Purchase Of Investment | — | — | — | — | — | — | $0 | $0 | ($795k) | ($795k) | |
| Sale Of Investment | — | — | — | — | $1k | $4k | $0 | $0 | — | $0 | |
| Decrease in cash and cash equivalents | $1.2m | $39.1m | ($10.0m) | ($12.2m) | $1.7m | ($13.3m) | ($2.7m) | ($623k) | ($1.7m) | — | |
| Exchange difference on cash and cash equivalents | ($45k) | $10k | ($144k) | ($649k) | $122k | ($196k) | ($357k) | $100k | ($35k) | — | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | ($13.3m) | ($2.7m) | ($623k) | ($1.7m) | — | |
| Interest Paid Classified As Financing Activities | ($171) | $134k | $129k | $70k | $63k | $49k | $22k | $9k | ($2k) | — |